CTS™ B-27™ Supplement XenoFree, minus insulin (50X)

CTS B-27 Supplement XenoFree, minus insulin, is a cGMP-manufactured, serum-free supplement designed to meet regulatory requirements for cell therapy manufacturing. It supports the growth and differentiation of a variety of cell types derived from pluripotent stem cells (PSCs). The absence of insulin makes this formulation ideal for the derivation of cardiomyocytes and mesodermal cells or the cultivation of PSC-derived cells where the presence of insulin causes interference.

CTS quality

Gibco CTS products are manufactured at a site that uses methods and controls that conform with cGMP for medical devices, 21 CFR Part 820. Our FDA-registered manufacturing sites are ISO 13485– and ISO 9001–certified.

Accompanied by documentation to support your regulatory filing

• Access to our Drug Master File (DMF) or Regulatory Support File (RSF)
• Traceability documentation—Certificate of Origin, Certificate of Analysis, and Safety Data Sheet

Reduced risk from animal-origin materials and human-derived components

CTS B-27 Supplement XenoFree minus Insulin is formulated with human-derived components and AOF recombinant components. To help reduce viral clearance risks, the use of human-derived components has been minimized and human-derived components are limited to materials that help meet regulatory standards for donor qualification, viral testing, and viral inactivation.

CTS B-27 Supplement XenoFree minus Insulin was specifically designed for use in cell therapy applications by making targeted modifications to the classic serum-free B-27 Supplement. CTS B-27 Supplement XenoFree minus Insulin supports the robust growth, expansion and differentiation of stem cells, making it a valuable addition to any cell therapy protocol where cGMP standards are required.